AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is conducting a Phase I clinical study titled ‘Safety and Tolerability of AZD5148 in Japanese Participants.’ The study aims to evaluate the safety, tolerability, and pharmacokinetics of a single dose of AZD5148 in healthy Japanese adults, highlighting its significance in advancing preventive healthcare measures.
The intervention being tested is AZD5148, administered as either an intramuscular (IM) injection or an intravenous (IV) bolus. This drug is designed to assess its safety and pharmacokinetic profile in the target population.
The study is interventional with a randomized allocation and a parallel intervention model. It employs a quadruple masking approach, ensuring that participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocation. The primary purpose of the study is prevention.
The study began on October 31, 2024, with an estimated primary completion date yet to be announced. The last update was submitted on August 1, 2025, indicating ongoing progress in the study.
This update could positively influence AstraZeneca’s stock performance by showcasing its commitment to innovative healthcare solutions. As the study progresses, investor sentiment may be bolstered by potential advancements in preventive medicine, positioning AstraZeneca favorably against competitors in the pharmaceutical industry.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.